ORGANIZATION

• Re-Pricing Rules Need Drastic Overhaul, Possible Abolishment Should Be Discussed for Z2: FPMAJ
  June 14, 2016

• FPMAJ Report Warns of Repercussions from Sovaldi Price Slash
  June 14, 2016

• Reimbursement Prices Kept Unchanged for Over 20% of Drugs: FPMAJ Survey
  June 13, 2016

• FPMAJ Wants to Avoid Narrowing-Down of Premium-Eligible Products: Kamoya
  June 13, 2016

• FPMAJ Drug Pricing Affairs Chief Lashes Out at Proposed Out-of-Cycle Re-Pricing
  June 13, 2016

• 9 Pharma-Related Companies to Join to Global Health Innovative Technology Fund
  June 8, 2016

• Japan Is at Crossroads, Must Carry On Its Pro-Innovation Policies: PhRMA Chairman
  June 3, 2016

• PhRMA Still “Concerned” about Anti-Innovation Policies despite Tax Decision: Japan Chief
  June 2, 2016

• Biosimilar Policies Shouldn’t Threaten Biologics Development: EFPIA Japan
  May 31, 2016

• Astellas’s Hatanaka Elected as New JPMA President
  May 27, 2016

• Sumitomo Dainippon Pres. Tada Picked as New Chief of FPMAJ
  May 27, 2016

• No Need to Add Hep B Vaccines to Public Immunization Program: Drug Damage Watchdog
  May 13, 2016

• Citizen’s Group Says Kaketsuken Shouldn’t Profit from Suspension-Cleared Products, Surcharges Needed
  May 13, 2016

• EFPIA Takes to Nagata-cho to Call for Real Dialogue
  April 28, 2016

• National Univ. Hospital Council to Disclose Funding with Companies’ Names Not Affiliated with JPMA
  April 27, 2016

• JPMA Official Calls for Use of Academic Data in Drug Submissions
  April 26, 2016

• Quakes Injure 3, Cause Property Damage for 22 Companies: JPMA Survey
  April 20, 2016

• JPMA Sets Up Taskforce for Russia, Brazil, Mexico, Turkey
  April 18, 2016

• Contract Sales Reps in Japan Likely to Increase to 6,000 in 2021: Industry Group
  April 15, 2016

• Japan at a Crossroads as Investment Destination, World’s Eyes Riveted on Govt’s Signals: PhRMA Local Chief
  April 13, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 51
• 52
• 53
• 54
• 55
• 56
• 57
• 58
• 59
• …
• Next ›
• 最終 »